Atlas Trials

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Clinical trial NCT06465433 · RECRUITING

Trial details

NCT number
NCT06465433
Sponsor
Incyte Corporation
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hematologic Malignancies
Start date
2022-11-08
Primary completion
2027-08-29
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.